Postictal headache. Other headache syndrome
Conditions
Interventions
Intervention 1: Intervention group: 10 mg Rizatriptan from TEKAJ pharmaceutical company, immediately after one episodes of postictal headache will be administered for three months period . Interventio
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Patients with a current history of PIH according to International Headache Society (IHS) 2004 criteria. Patients with at least one predisposal headache attack per month for months prior to entering the study. The patients will be include to this study from epilepsy ward of Namazi hospital,Iran. The patients will be include to this study with at least age of 18 .
Exclusion criteria
Exclusion criteria: Patients have uncontrolled hypertension. Patients have ischemic heart disease. Patients have cardiac arrhythmias. Patients have previous stroke or transient ischemic attack. Patients have severe liver or renal impairment. Patients have any other severe or disabling medical condition. Patients have a history of alcohol or analgesic or psychotropic drug abuse. Patients have known hypersensitivity to study drugs. Patients who had demonstrated inadequate response to at least two triptans. Patients who currently use propranolol or ergotamine (and its derivatives) as a prophylactic agent. Patients who currently use MAO-inhibitors. Patients have psychogenetic non-epileptic seizure. Patients will be over 55 years old.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Migraine Disability Assessment score. Timepoint: Before the intervention and half an hour to two hours after the start of taking Rizatriptan. Method of measurement: The Migraine Disability Assessment questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMina Shahisavandi
Shiraz University of Medical Sciences
Outcome results
None listed